SCHEMBL804669

SCHEMBL804669

CC(C)CCCC(C)(F)F

nearest known ligand 0.42

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.42
CYP3A4 P08684 1/20 0.42
ALOX15 P16050 1/20 0.42
KMT2A Q03164 1/20 0.42
LMNA P02545 1/20 0.39
BLM P54132 1/20 0.33
PTPN2 P17706 1/20 0.32
PTPN1 P18031 1/20 0.32
CDC25B P30305 1/20 0.32
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17882175 0.92 LMNA (0.43) MEN1CYP3A4ALOX15KMT2ALMNA
SCHEMBL21453077 0.83 MEN1 (0.42) MEN1CYP3A4ALOX15KMT2ALMNA
SCHEMBL8377435 0.82
SCHEMBL28355881 0.81
SCHEMBL14981590 0.81 MAPK1 (0.33) ALDH1A1
SCHEMBL1191595 0.80 LMNA (0.41) MEN1CYP3A4ALOX15KMT2ALMNA
SCHEMBL26501077 0.80 LMNA (0.41) MEN1CYP3A4ALOX15KMT2ALMNA
SCHEMBL19545639 0.79 MEN1 (0.39) MEN1CYP3A4ALOX15KMT2ALMNA
SCHEMBL9908340 0.79 MEN1 (0.39) MEN1CYP3A4ALOX15KMT2ALMNA
SCHEMBL17070165 0.79 MEN1 (0.39) MEN1CYP3A4ALOX15KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11802132-B2 Small molecules for inducing selective protein degradation and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-10-31 US disclosed
US-11655216-B2 Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use MERCK SHARP & DOHME LLC (US) 2023-05-23 US disclosed
US-20180198167-A1 IONIC LIQUID ELECTROLYTES AND ELECTROCHEMICAL DEVICES COMPRISING SAME THE TRUSTEES OF BOSTON UNIVERSITY 2018-07-12 US disclosed
US-10017527-B2 KLK4 inhibitors UNIVERSITEIT ANTWERPEN (BE) 2018-07-10 US disclosed
US-9896459-B2 Azaindoles as respiratory syncytial virus antiviral agents JANSSEN SCIENCES IRELAND UC (IE) 2018-02-20 US disclosed
US-9655944-B2 Inhibitors of hepatitis C virus GILEAD SCIENCES, INC. (US) 2017-05-23 US disclosed
US-20170101427-A1 NOVEL KLK4 INHIBITORS UNIVERSITEIT ANTWERPEN (BE) 2017-04-13 US disclosed
US-20130011361-A1 PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE XENON PHARMACEUTICALS INC. (CA) 2013-01-10 US disclosed
US-20120070416-A1 Macrocyclic Proline Derived HCV Serine Protease Inhibitors ENANTA PHARMACEUTICALS, INC. 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10017527-B2 KLK4 inhibitors KLK4, KLK3, KLK1 MEN1 3183/4885CYP3A4 3405/4885ALOX15 4847/4885
US-20120070416-A1 Macrocyclic Proline Derived HCV Serine Protease Inhibitors PREP, PRSS1, PEPD MEN1 4449/4885CYP3A4 281/4885ALOX15 2521/4885
US-20130011361-A1 PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE SCD, SCD5, FADS2 MEN1 4871/4885CYP3A4 228/4885ALOX15 344/4885
US-11655216-B2 Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use NR1H2, NR1H3, NR1H4 MEN1 4463/4885CYP3A4 77/4885ALOX15 618/4885
US-11802132-B2 Small molecules for inducing selective protein degradation and uses thereof BAZ2A, BRD3, BRPF3 MEN1 3068/4885CYP3A4 4681/4885ALOX15 3481/4885
US-20170101427-A1 NOVEL KLK4 INHIBITORS KLK4, KLK3, KLK1 MEN1 3716/4885CYP3A4 3606/4885ALOX15 4867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.